Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition.
Ontology highlight
ABSTRACT: Purpose: Adenoid cystic carcinoma (ACC) is a rare cancer arising from the major or minor salivary gland tissues of the head and neck. There are currently no approved systemic agents or known radiosensitizers for ACC. Unlike the more common head and neck squamous cell carcinomas that frequently harbor TP53 mutations, ACCs contain TP53 mutations at a rate of <5%, rendering them an attractive target for MDM2 inhibition.Experimental Design: We report the successful establishment and detailed characterization of a TP53-WT ACC patient-derived xenograft (PDX), which retained the histologic features of the original patient tumor. We evaluated this model for response to the MDM2 inhibitor AMG 232 as monotherapy and in combination with radiotherapy.Results: AMG 232 monotherapy i
SUBMITTER: Prabakaran PJ
PROVIDER: S-EPMC5641244 | biostudies-literature | 2017 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA